About Vigil Neuroscience Inc.

Vigil Neuroscience Inc., founded in 2020, is developing innovative therapies for neurodegenerative diseases by targeting microglia, the brain's immune cells that play critical roles in neurodegeneration and neuroinflammation. The company's approach focuses on modulating microglial function to treat diseases like Alzheimer's and ALS. VIGL stock price reflects investor interest in the company's novel approach to neurodegenerative disease treatment.

Led by CEO Ivana Magov?evi?-Liebisch, Vigil Neuroscience has assembled a team with deep expertise in neuroscience and drug development to advance its microglial-targeted platform. The management team combines neurobiology expertise with proven drug development capabilities in neurodegenerative diseases. Leadership's strategic focus on precision medicine approaches to neurodegeneration has been important for building a differentiated pipeline and influencing VIGL stock price potential.

Vigil operates by developing therapies that target microglial function and neuroinflammation to treat neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis (ALS), and other conditions characterized by neuroinflammation. The company's platform focuses on genetically defined patient populations with microglial dysfunction. With neurodegenerative diseases representing massive unmet medical needs, growing understanding of microglial roles in neurodegeneration, and Vigil's precision medicine approach to targeting specific genetic subtypes, VIGL offers investors exposure to innovative neurodegenerative disease therapeutics with potential for meaningful patient impact in conditions with few effective treatments.